Surgical Management of Hepatic Metastases of Colorectal Cancer
Surgical Management of Hepatic Metastases of Colorectal Cancer
复制标题
DOI：
10.1016/j.hoc.2014.09.003
复制
发表时间：
2015-02-01
影响因子：
2.4
通讯作者：
D'Angelica, Michael I.
中科院分区：
文献类型：
--
作者：
Smith, J. Joshua;D'Angelica, Michael I.
对于20%的可切除结直肠肝转移（CRLM）患者，肝切除术是安全、有效和潜在的治愈性。与原发性和转移性肿瘤个体相关的因素以及临床风险评分方案是最佳预后因素，尽管难以定义应排除手术的可切除、肝脏限制性CRLM患者组。转移性结直肠癌的全身化疗作为切除术后的辅助治疗已改善了总生存率，但并未改善总生存率。全身和/或肝动脉灌注化疗转为完全切除是不可切除CRLM患者的适当目标。
For the 20% of patients with resectable colorectal liver metastases (CRLM), hepatic resection is safe, effective and potentially curative. Factors related to the primary and metastatic tumors individually and in clinical risk-scoring schemes are the best prognostic factors, although it is difficult to define patient groups with resectable, liver-limited CRLM that should be excluded from surgery. Systemic chemotherapy for metastatic colorectal cancer has improved but does not improve overall survival as adjuvant therapy after resection. Conversion to complete resection with systemic and/or hepatic arterial infusion chemotherapy is an appropriate goal for patients with unresectable CRLM.